PPARA and metabolic syndrome: The synthesis of new drug generation - PPARα/γ dual agonists - connecting positive influences on both lipid and glucose metabolism has been recently developed as a response to the treatment challenge of co-existing type 2 diabetes mellitus with dyslipidemia.